More aggressive FTC begins targeting drug mergers and industry middlemen
Led by an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is acting against pharmaceutical companies and industry intermediaries as part of the Biden administration’s push to lower drug prices over the counter. the pharmacy. On May 16, the FTC filed a lawsuit to block the merger of drugmakers Amgen and Horizon Therapeutics, … Read more